Loxo Oncology, Inc.
Clinical trials sponsored by Loxo Oncology, Inc., explained in plain language.
-
New hope for blood cancer patients: experimental drug pirtobrutinib enters phase 2 trial
Disease control Recruiting nowThis study tests three different doses of an experimental drug called pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or didn't respond to a previous type of targeted therapy (a BTK inhibitor). The goal is…
Phase: PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug pirtobrutinib takes on standard therapy in major CLL trial
Disease control Recruiting nowThis phase 3 study compares a new drug, pirtobrutinib, to the standard drug ibrutinib in people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 662 participants, who may or may not have had prior treatment, will receive one of the two drugs. The goal is to …
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 12, 2026 13:39 UTC